Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study Summary This phase II study explored the efficacy of adding sintilimab (an anti-PD-1 immunotherapy) Read More